Nepikastat

Nepikastat
Nazivi
	IUPAC naziv 5-(aminometil)-1-[(2S)-5,7-difluoro-1,2,3,4-tetrahidronaftalen-2-il]-1,3-dihidro-2H-imidazol-2-tion
	Drugi nazivi SYN-117
Identifikacija
CAS broj	173997-05-2;
3D model (Jmol)	interaktivna slika;
ChemSpider	7971947;
MeSH	Nepicastat
PubChemC ID	9796181;
	SMILES Fc1cc3c(c(F)c1)CC[C@H](N2/C(=C\NC2=S)CN)C3; ; ; ; ; ;
Svojstva
Hemijska formula	C14H15F2N3S
Molarna masa	295,35 g/mol
	Ukoliko nije drugačije napomenuto, podaci se odnose nastandardno stanjematerijala (na 25 °C [77 °F], 100 kPa).
	verifikuj(šta je?)
	Reference infokutije

On je je ispitan kao potencijalni lek kongestivnozatajenje srca,i pokazano je da je dobro tolerisan u toj ulozi.^[4]2012, Klinička ispitivanjakoja su istraživala moguću primenu nepikastata u lečenjuposttraumatskog stresnog poremećaja(PTSD) ikokainske zavisnostisu završena 2012.^[5]^[6]

Sinteza

Jedan od mogućih sintetičkih puteva je^[7]:

^Li Q, Cheng T, Wang Y, Bryant SH (2010).„PubChem as a public resource for drug discovery.”.Drug Discov Today.15(23-24): 1052—7.PMID 20970519.doi:10.1016/j.drudis.2010.10.003.уреди
^Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”.Annual Reports in Computational Chemistry.4:217—241.doi:10.1016/S1574-1400(08)00012-1.
^Stanley WC; Li B; Bonhaus DW; et al. (1997).„Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase”.Br J Pharmacol.121(8): 1803—9.PMC1564872 .PMID 9283721.doi:10.1038/sj.bjp.0701315.
^Hegde SS, Friday KF (1998). „Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure”.Current pharmaceutical design.4(6): 469—79.PMID 10197057.
^„Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD)”.ClinicalTrials.gov.U.S. National Institutes of Health. 4. 6. 2008.Retrieved on February 1, 2012.
^„Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers”.ClinicalTrials.gov.U.S. National Institutes of Health. 15. 8. 2008.Retrieved on February 1, 2012.
^U.S. Patent 5.719.280